COCP Stock UPDATES Cocrystal Pharma Inc. (COCP) 0.5500 11/02/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 2, 2014 at 9:11 PM

Cocrystal Pharma Inc. (COCP) 0.5500 $COCP

Cocrystal Pharma Develops Novel Ebola Screening Technology
Marketwired - Thu Oct 23, 8:26AM CDT
Cocrystal Pharma, Inc. (OTCBB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.
OPK: 8.35 (-0.04)

Cocrystal Pharma records higher Q2 operating expenses of USD1.4m
M2 - Mon Aug 18, 7:46AM CDT
Biotechnology company Cocrystal Pharma (OTC BB:COCP) stated on Friday that its operating expenses were USD1.4m for the second quarter ended 30 June 2014.

Cocrystal Pharma Reports Second Quarter Financial Results
Marketwire - Fri Aug 15, 6:30AM CDT
Cocrystal Pharma, Inc. (the "Company"

(OTCBB: COCP) (OTCQB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported financial results for the second quarter ended June 30, 2014.

Cocrystal Pharma, Inc. - "World Hepatitis Day and a Continued Global Unmet Medical Need"
ACCESSWIRE - Mon Jul 28, 8:47AM CDT
New York, NY / July 28, 2014 / Cocrystal Pharma, Inc. (OTCBB: COCP) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, Dr. Gary Wilcox. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

OTC Stocks Trading News: Cocrystal Pharma, Inc. Minerco Resources, Inc. MediJane Holdings, Inc. Applied DNA Sciences, Inc. mCig Inc
PR Newswire Europe - Tue Jul 22, 7:02AM CDT
LONDON, July 22, 2014 /PRNewswire/ --

H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
CVM: 0.67 (-0.02), EBS: 22.62 (+0.27), GSK: 45.49 (+0.35), NNVC: 3.81 (-0.01), SIGA: 1.41 (+0.06), JNJ: 107.78 (+0.74), OPK: 8.35 (-0.04), XOMA: 4.29 (-0.28), NVS: 92.69 (+0.74)

Rhinovirus Infection - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rd8bmd/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rhinovirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhinovirus Infection and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Boehringer Ingelheim GmbH - Theraclone Sciences, Inc. - Alios BioPharma, Inc. - Cocrystal Pharma, Inc. - Sealife PHARMA GMBH - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rd8bmd/rhinovirus
BOTA: 2.45 (+0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Heineken Hit with €111M Judgment—A Precedent Set

A Brew of Legal Consequences for Heineken If this isn't a financial wake-up call for the brewing giant, I don't know what is. In the latest twist of corporate accountability, the Amsterdam District Court has ordered Heineken and its Greek subsidiary, Athenian Brewery, to cough up a whopping €111 million. And we're not just talking pocket change—this ruling speaks...

Doximity Lawsuit: Investors Face November Deadline

Hard Knocks for Doximity Investors Alright, so this isn't the place I usually find myself at that hour, but we're living in wild times if you're clinging to Doximity (NYSE:DOCS) shares. Listen up, because those lawyers are chiming in and they ain't just whistling Dixie. If you bought into DOCS between August 2024 and May 2026 and watched your investment bleed red ink,...

Fresenius Revamps U.S. Kidney Care with multiFiltratePRO

Fresenius Takes a Giant Leap in Kidney Care Fresenius Medical Care is breaking new ground in the U.S., marking a significant milestone with the introduction of the multiFiltratePRO System for critically ill patients battling acute kidney injury (AKI). This isn't some run-of-the-mill equipment upgrade. It's an evolution in how critical care teams manage continuous kidney...

Cesar Alvarez Honored with Prestigious Miami Award

Cesar Alvarez's Legacy Honored in Miami The Greater Miami Chamber of Commerce's 2026 Sand in My Shoes® Award has found its latest recipient in Cesar L. Alvarez, the Senior Chairman of Greenberg Traurig, P.A. It wasn't just a ceremony—this was a gathering of more than 800 of Miami's business and community power players on October 15, 2026. And man, did it shine a bright...

FFR Set to Unveil Strategy at Nasdaq Event in NYC

An Exciting Day for FFR on Wall Street Hold onto your hats, investors! FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is about to make a splash in the big leagues at its much-anticipated Nasdaq listing ceremony. Slated for October 26 at the iconic Nasdaq Tower in NYC, it's a day that could pivot the company’s future centerpiece strategy, jacking up anticipation like...

Red Banyan Wins Inc. Power Partner Award for 3rd Year

Red Banyan: A Powerhouse in B2B Support Red Banyan isn't just any player in the communications game; it's carved out a reputation as the go-to when businesses hit rough waters. You see, for the third consecutive year, this Fort Lauderdale-based firm bagged the Inc. Power Partner Award—a nod to its clout in the B2B arena. This accolade ain't about fancy ads; it's about...

Tigo Energy Faces Rough Waters Amidst Class Action

Shareholders Feel the Burn with Tigo's Stock Plunge The latest twist in the Tigo Energy saga has left investors reeling. The big hitters like Glancy Prongay Wolke & Rotter LLP have stepped into the ring, shaking the trees over allegations of securities fraud that have shaken confidence in NASDAQ:TYGO. In just a day, Tigo's shares have nose-dived over 36% thanks to this...

Vermilion Energy Sets Dates for Earnings and Calls

The Anticipation Around Vermilion's Upcoming Results There's a buzz in the air about Vermilion Energy Inc.'s upcoming Q3 2026 financial results. Slated to hit the wires November 4th, before the sun rises on Wall Street, folks in the trade have their eyes peeled to parse through any morsels of data. The question on everyone's mind? Whether they're making the right moves to...

American Lung Association Tackles Indoor Pollution

The Unseen Threat Lurking Indoors When you think about air pollution, your mind probably jumps to smog-choked city streets. But, surprise! The air inside your cozy living room could actually be pulling a fast one on you, being two to five times filthier than what’s outside. Now, that’s a hair-raising thought. A Closer Look at Indoor Air Hazards Folks don’t usually...

Decoding New Loyalty Strategies with TrueLoyal In this cutthroat market, loyalty's the name of the game, and TrueLoyal just rolled out a sharp new tool that's got me raising an eyebrow. Their Advanced Analytics is shaking up the way brands look at their loyalty programs. This ain't your granddad's analytics tool—it promises to cut the fat and put your spending where it...